Results 11 to 20 of about 354,007 (274)

The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic [PDF]

Frontiers in Molecular Biosciences, 2020
The emergence and global impact of COVID-19 has focused the scientific and medical community on the pivotal influential role of respiratory viruses as causes of severe pneumonia, on the understanding of the underlying pathomechanisms, and on potential ...
Ludwig Aigner, Ludwig Aigner, Ludwig Aigner, Frank Pietrantonio, Diana Marisa Bessa de Sousa, Diana Marisa Bessa de Sousa, Johanna Michael, Johanna Michael, Daniela Schuster, Herbert Anton Reitsamer, Herbert Anton Reitsamer, Horst Zerbe, Michael Studnicka   +12 more
doaj   +3 more sources

The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice [PDF]

International Journal of Molecular Sciences, 2021
Alzheimer’s disease (AD) is the most common form of dementia. In particular, neuroinflammation, mediated by microglia cells but also through CD8+ T-cells, actively contributes to disease pathology.
Rodolphe Poupardin, Ludwig Aigner, Herbert Reitsamer   +2 more
exaly   +3 more sources

Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? [PDF]

The Scientific World Journal, 2010
The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the therapy of exercise- and aspirin-induced asthma.
Gregory R. Tintinger, Charles Feldman, Annette J. Theron, Ronald Anderson   +3 more
doaj   +3 more sources

Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease. [PDF]

Int J Mol Sci, 2021
Parkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available.
Wallin J, Svenningsson P.
europepmc   +2 more sources

The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies. [PDF]

Neurotherapeutics, 2020
Dementia with Lewy bodies (DLB) represents a huge medical need as it accounts for up to 30% of all dementia cases, and there is no cure available. The underyling spectrum of pathology is complex and creates a challenge for targeted molecular therapies ...
Marschallinger J, Altendorfer B, Rockenstein E, Holztrattner M, Garnweidner-Raith J, Pillichshammer N, Leister I, Hutter-Paier B, Strempfl K, Unger MS, Chishty M, Felder T, Johnson M, Attems J, Masliah E, Aigner L.   +15 more
europepmc   +2 more sources

Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury

Hepatology, EarlyView., 2022
Background and Aim: Drug‐induced liver injury (DILI) is a common disorder that involves both direct liver cell toxicity and immune activation. The bile acid receptor, G‐protein‐coupled bile acid receptor 1 (GPBAR1; Takeda G‐protein‐coupled receptor 5 ...
M. Biagioli, S. Marchianò, C. Di Giorgio, Rosalinda Roselli, M. Bordoni, Rachele Bellini, Bianca Fiorillo, V. Sepe, B. Catalanotti, Chiara Cassiano, M. C. Monti, E. Distrutti, A. Zampella, S. Fiorucci   +13 more
semanticscholar   +2 more sources

Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) [PDF]

World Allergy Organization Journal, 2021
Background: There are limited real-world studies on the differences in leukotriene receptor antagonists (LTRA), H1-antihistamines (H1-AH), and inhaled corticosteroids (ICS) associated neuropsychiatric events.
Sainan Bian, Lisha Li, Zixi Wang, Le Cui, Yingyang Xu, Kai Guan, Bin Zhao, Lianglu Wang, Jia Yin   +8 more
doaj   +2 more sources

Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial [PDF]

Frontiers in Pharmacology, 2023
Background: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-line therapy for this condition. However, it has only a minor impact on weight loss in some patients.Aim: This study aimed to evaluate the effectiveness ...
Eman El-Khateeb, Eman El-Khateeb, Eman I. El-Berri, Esraa M. Mosalam, Mohamed Z. Nooh, Shimaa Abdelsattar, Amira M. Alghamdi, Sarah Alrubia, Mahmoud S. Abdallah   +8 more
doaj   +2 more sources

Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope [PDF]

Frontiers in Pharmacology, 2023
Background: Adenoidal hypertrophy (AH) is one of the most common causes of upper airway obstruction in children. Drug and surgical treatment are the typical treatment of AH.
Zhengying Wang, Zhengying Wang, Xiuling Wu, Xiuling Wu, Jinghong Liu, Jinghong Liu, Yu Wang, Yu Wang, Yue Zhang, Yan Wu, Yingxue Kang, Yingxue Kang, Ronghai Zhang, Ronghai Zhang, Jin Li, Jin Li, Delong Liu   +16 more
doaj   +2 more sources

The efficacy and safety of selective H1-antihistamine versus leukotriene receptor antagonist for seasonal allergic rhinitis: a meta-analysis. [PDF]

PLoS One, 2014
Background Both selective H1-antihistamine (SAH) and leukotriene receptor antagonist (LTRA) have been shown to be effective in treating patients with seasonal allergic rhinitis (SAR), but it is still uncertain which treatment option is optimal. This meta-
Xu Y, Zhang J, Wang J.
europepmc   +2 more sources